nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—RYR3—endometrium—polycystic ovary syndrome	0.0493	0.122	CbGeAlD
Dantrolene—RYR3—uterus—polycystic ovary syndrome	0.0455	0.113	CbGeAlD
Dantrolene—RYR3—pituitary gland—polycystic ovary syndrome	0.0446	0.111	CbGeAlD
Dantrolene—RYR3—adipose tissue—polycystic ovary syndrome	0.0445	0.11	CbGeAlD
Dantrolene—RYR3—adrenal gland—polycystic ovary syndrome	0.0399	0.0988	CbGeAlD
Dantrolene—RYR3—vagina—polycystic ovary syndrome	0.037	0.0916	CbGeAlD
Dantrolene—RYR3—Stimuli-sensing channels—TRPV6—polycystic ovary syndrome	0.0344	0.0655	CbGpPWpGaD
Dantrolene—RYR1—uterus—polycystic ovary syndrome	0.0326	0.0808	CbGeAlD
Dantrolene—RYR3—Stimuli-sensing channels—SCNN1A—polycystic ovary syndrome	0.0311	0.0593	CbGpPWpGaD
Dantrolene—RYR1—adrenal gland—polycystic ovary syndrome	0.0286	0.0709	CbGeAlD
Dantrolene—RYR1—vagina—polycystic ovary syndrome	0.0265	0.0657	CbGeAlD
Dantrolene—CYP3A4—urine—polycystic ovary syndrome	0.026	0.0644	CbGeAlD
Dantrolene—RYR1—Stimuli-sensing channels—TRPV6—polycystic ovary syndrome	0.0253	0.0483	CbGpPWpGaD
Dantrolene—RYR1—endocrine gland—polycystic ovary syndrome	0.0248	0.0615	CbGeAlD
Dantrolene—RYR1—Stimuli-sensing channels—SCNN1A—polycystic ovary syndrome	0.0229	0.0437	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—TRPV6—polycystic ovary syndrome	0.0224	0.0428	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—SCNN1A—polycystic ovary syndrome	0.0203	0.0387	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—ADRA1D—polycystic ovary syndrome	0.0182	0.0347	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—ADRA1B—polycystic ovary syndrome	0.0177	0.0337	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—TRPV6—polycystic ovary syndrome	0.0165	0.0315	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—SCNN1A—polycystic ovary syndrome	0.015	0.0285	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—ADRA1D—polycystic ovary syndrome	0.0134	0.0255	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—ADRA1A—polycystic ovary syndrome	0.0134	0.0255	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—ADRA1B—polycystic ovary syndrome	0.013	0.0249	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—ADRB3—polycystic ovary syndrome	0.0129	0.0246	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IGFBP1—polycystic ovary syndrome	0.011	0.021	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.011	0.0209	CbGpPWpGaD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—AKR1C2—polycystic ovary syndrome	0.0105	0.0199	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—ADRA1A—polycystic ovary syndrome	0.00988	0.0188	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—ADRB3—polycystic ovary syndrome	0.00951	0.0181	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—CAMK2D—polycystic ovary syndrome	0.00929	0.0177	CbGpPWpGaD
Dantrolene—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.00921	0.128	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—CAMK2D—polycystic ovary syndrome	0.009	0.0172	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IGFBP1—polycystic ovary syndrome	0.00814	0.0155	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.00808	0.0154	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.00781	0.0149	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—ATF1—polycystic ovary syndrome	0.00778	0.0148	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.00706	0.0135	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—ADRB2—polycystic ovary syndrome	0.00697	0.0133	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—CAMK2D—polycystic ovary syndrome	0.00685	0.0131	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—CAMK2D—polycystic ovary syndrome	0.00663	0.0126	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—GNAS—polycystic ovary syndrome	0.00646	0.0123	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—GNAS—polycystic ovary syndrome	0.00626	0.0119	CbGpPWpGaD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—polycystic ovary syndrome	0.00582	0.0111	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.00576	0.011	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—ATF1—polycystic ovary syndrome	0.00573	0.0109	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.00521	0.00992	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—ADRB2—polycystic ovary syndrome	0.00514	0.00979	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—GNAS—polycystic ovary syndrome	0.00476	0.00908	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—GNAS—polycystic ovary syndrome	0.00461	0.0088	CbGpPWpGaD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—polycystic ovary syndrome	0.00448	0.00854	CbGpPWpGaD
Dantrolene—Lightheadedness—Metformin—polycystic ovary syndrome	0.00433	0.0602	CcSEcCtD
Dantrolene—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00431	0.0107	CbGeAlD
Dantrolene—Pain in extremity—Metformin—polycystic ovary syndrome	0.00352	0.0489	CcSEcCtD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—SULT2A1—polycystic ovary syndrome	0.00322	0.00614	CbGpPWpGaD
Dantrolene—CYP3A4—Farnesoid X Receptor  Pathway—SULT2A1—polycystic ovary syndrome	0.00295	0.00562	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.00295	0.00562	CbGpPWpGaD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—polycystic ovary syndrome	0.00281	0.00536	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.00274	0.00522	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—SULT2A1—polycystic ovary syndrome	0.00272	0.00518	CbGpPWpGaD
Dantrolene—Drowsiness—Metformin—polycystic ovary syndrome	0.00271	0.0376	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.00251	0.00478	CbGpPWpGaD
Dantrolene—Hepatitis—Metformin—polycystic ovary syndrome	0.00243	0.0338	CcSEcCtD
Dantrolene—Flushing—Metformin—polycystic ovary syndrome	0.00226	0.0314	CcSEcCtD
Dantrolene—Chills—Metformin—polycystic ovary syndrome	0.00218	0.0303	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.00217	0.00414	CbGpPWpGaD
Dantrolene—Erythema—Metformin—polycystic ovary syndrome	0.00212	0.0294	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.0021	0.00401	CbGpPWpGaD
Dantrolene—Dysgeusia—Metformin—polycystic ovary syndrome	0.00207	0.0288	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.00202	0.00385	CbGpPWpGaD
Dantrolene—Vision blurred—Metformin—polycystic ovary syndrome	0.002	0.0277	CcSEcCtD
Dantrolene—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00196	0.0273	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—polycystic ovary syndrome	0.00194	0.0037	CbGpPWpGaD
Dantrolene—Malaise—Metformin—polycystic ovary syndrome	0.00191	0.0265	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.00185	0.00352	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL6—polycystic ovary syndrome	0.00183	0.00349	CbGpPWpGaD
Dantrolene—Hypertension—Metformin—polycystic ovary syndrome	0.00183	0.0254	CcSEcCtD
Dantrolene—Myalgia—Metformin—polycystic ovary syndrome	0.0018	0.025	CcSEcCtD
Dantrolene—Discomfort—Metformin—polycystic ovary syndrome	0.00178	0.0247	CcSEcCtD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—polycystic ovary syndrome	0.00178	0.00339	CbGpPWpGaD
Dantrolene—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00169	0.0235	CcSEcCtD
Dantrolene—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00167	0.0232	CcSEcCtD
Dantrolene—Anorexia—Metformin—polycystic ovary syndrome	0.00165	0.0229	CcSEcCtD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1A1—polycystic ovary syndrome	0.00162	0.00308	CbGpPWpGaD
Dantrolene—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00157	0.0219	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.00155	0.00295	CbGpPWpGaD
Dantrolene—Somnolence—Metformin—polycystic ovary syndrome	0.00154	0.0213	CcSEcCtD
Dantrolene—Dyspepsia—Metformin—polycystic ovary syndrome	0.00152	0.0211	CcSEcCtD
Dantrolene—Decreased appetite—Metformin—polycystic ovary syndrome	0.0015	0.0209	CcSEcCtD
Dantrolene—Fatigue—Metformin—polycystic ovary syndrome	0.00149	0.0207	CcSEcCtD
Dantrolene—CYP3A4—Xenobiotics—CYP1A1—polycystic ovary syndrome	0.00149	0.00283	CbGpPWpGaD
Dantrolene—Constipation—Metformin—polycystic ovary syndrome	0.00148	0.0205	CcSEcCtD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1A1—polycystic ovary syndrome	0.00143	0.00272	CbGpPWpGaD
Dantrolene—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00142	0.0198	CcSEcCtD
Dantrolene—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00141	0.0196	CcSEcCtD
Dantrolene—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—polycystic ovary syndrome	0.00137	0.00262	CbGpPWpGaD
Dantrolene—Urticaria—Metformin—polycystic ovary syndrome	0.00137	0.0191	CcSEcCtD
Dantrolene—Abdominal pain—Metformin—polycystic ovary syndrome	0.00137	0.019	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—polycystic ovary syndrome	0.00135	0.00257	CbGpPWpGaD
Dantrolene—Asthenia—Metformin—polycystic ovary syndrome	0.00124	0.0172	CcSEcCtD
Dantrolene—Pruritus—Metformin—polycystic ovary syndrome	0.00122	0.017	CcSEcCtD
Dantrolene—Diarrhoea—Metformin—polycystic ovary syndrome	0.00118	0.0164	CcSEcCtD
Dantrolene—Dizziness—Metformin—polycystic ovary syndrome	0.00114	0.0159	CcSEcCtD
Dantrolene—Vomiting—Metformin—polycystic ovary syndrome	0.0011	0.0153	CcSEcCtD
Dantrolene—Rash—Metformin—polycystic ovary syndrome	0.00109	0.0151	CcSEcCtD
Dantrolene—Dermatitis—Metformin—polycystic ovary syndrome	0.00109	0.0151	CcSEcCtD
Dantrolene—Headache—Metformin—polycystic ovary syndrome	0.00108	0.015	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—polycystic ovary syndrome	0.00104	0.00198	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—polycystic ovary syndrome	0.00103	0.00196	CbGpPWpGaD
Dantrolene—Nausea—Metformin—polycystic ovary syndrome	0.00103	0.0143	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—AKR1C2—polycystic ovary syndrome	0.000974	0.00186	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—polycystic ovary syndrome	0.000967	0.00184	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—polycystic ovary syndrome	0.000954	0.00182	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP19A1—polycystic ovary syndrome	0.000947	0.0018	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.000843	0.00161	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.000784	0.00149	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.000765	0.00146	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1A1—polycystic ovary syndrome	0.000763	0.00145	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.000755	0.00144	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.000735	0.0014	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.00062	0.00118	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000617	0.00118	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000609	0.00116	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000542	0.00103	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.000506	0.000964	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.0005	0.000953	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.000499	0.000951	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.00046	0.000877	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.000448	0.000854	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.000442	0.000842	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.000417	0.000795	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.000416	0.000794	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.000411	0.000783	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.000373	0.000711	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.00033	0.000628	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.000325	0.00062	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000266	0.000506	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000262	0.000499	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	0.000234	0.000445	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	0.000214	0.000407	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	0.000214	0.000407	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	0.000199	0.000379	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	0.000198	0.000378	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	0.000169	0.000322	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	0.000169	0.000322	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	0.000142	0.00027	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	0.000134	0.000256	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	0.000128	0.000244	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	0.000114	0.000218	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	0.000109	0.000208	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	9.93e-05	0.000189	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	9.7e-05	0.000185	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	9.4e-05	0.000179	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	8.65e-05	0.000165	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	8.38e-05	0.00016	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	8.07e-05	0.000154	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	7.76e-05	0.000148	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	7.66e-05	0.000146	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	7.23e-05	0.000138	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	7.12e-05	0.000136	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TH—polycystic ovary syndrome	6.16e-05	0.000117	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	5.99e-05	0.000114	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	5.64e-05	0.000107	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	5.03e-05	9.59e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	4.79e-05	9.14e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	4.54e-05	8.66e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	4.24e-05	8.07e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	3.43e-05	6.55e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	3.39e-05	6.46e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—INS—polycystic ovary syndrome	3.37e-05	6.42e-05	CbGpPWpGaD
